EFFICIENCY OF PSO MEDIS AGENTS TOPICAL APPLICATION FOR PSORIASIS SCALP MANIFESTATIONS
Objective. Assessment of efficiency of PSO Medis agents (lotion, shampoo) produced by Kamedis, Israel, when applied topically by patients having psoriasis scalp manifestations was the purpose of the study. Materials and methods. The PSO Media agents topical application efficiency was assessed in 21 patients suffering from vulgar psoriasis requiring no systemic treatment. Inclusion and exclusion criteria were developed and a standard pattern for questionnaires used for the agents application efficiency assessment was offered before the study beginning. The total period of every patient observation was 42 days. The PASI calculation standard scale for scalp was used for the psoriatic process severity objective evaluation initially and for the agent topical application efficiency assessment in the dynamics. The PDI questionnaire was used for assessing the patient's quality of life in the studied group initially and finally by the Tix-box method. The quantitative visual scale for self-appraisal (QVSSA) of the psoriasis course severity (0 to 10 points) was used at each of four doctor visits. Results. Every patient tolerated the topical PSO Medis agents treatment satisfactorily. Neither allergic nor toxic reaction was registered. A positive dynamics had been observed as early as in 2 weeks of the products application. The total PASI value for scalp tended to a reduction by 39.5% (P<0.001) as compared with the initial values allowing consider the therapy resulting in a mild improvement at that stage. At the second control (Visit 3) the PASI value reduced by 67.7% (P<0,001) vs the initial value. Thus, by Day 28 the product efficiency might be considered as an improvement. The PASI value reduced by 75.5% by Day 42 vs the initial value and that result might be considered an evident improvement. Therefore the therapy should be acknowledged to be efficient. The patients were evaluating the psoriasis course severity more highly during the study performance the highest effect being achieved by Visit 4. The QVSSA patients' estimates reduced reliably by 78.7% (P<0.001) vs the initial values at the final stage tending to zero. Conclusion. PSO Medis agents produced by Kamedis, Israel, may be considered topical agents for treating patients suffering from scalp vulgar psoriasis requiring no systemic treatment efficient when used for 28 days and highly efficient when used for 42 days. Course application of PSO Medis agents impacts positively on the basic parameters of the quality of life psoriatic patients.